Structural and functional characterization of C0021158, a high-affinity monoclonal antibody that inhibits Arginase 2 function via a novel non-competitive mechanism of action

by Mark Austin, Daniel Burschowsky, Denice T.Y. Chan, Lesley Jenkinson, Stuart Haynes, Agata Diamandakis, Chitra Seewooruthun, Alexandra Addyman, Sebastian Fiedler, Stephanie Ryman, Jessica Whitehouse, Louise H. Slater, Andreas V. Hadjinicolaou, Uzi Gileadi, Ellen Gowans, Yoko Shibata, Michelle Barnard, Teresa Kaserer, Pooja Sharma, Nadia M. Luheshi, Robert W. Wilkinson, Tristan J. Vaughan, Sarah V. Holt, Vincenzo Cerundolo, Mark D. Carr, Maria A. T. Groves
Published 2020-01-01

Liposomal T cell engager and re-director for tumor cell eradication in cancer immunotherapy

by Fang Xie, Luchen Zhang, Sanyuan Shi, Anjie Zheng, Jiaxing Di, Shanshan Jin, Xuguang Miao, Fenglan Wu, Xiaolong Chen, Yanhong Zhang, Xiaohui Wei, Yuhong Xu
Published 2022-12-01

Full-length recombinant antibodies from Escherichia coli: production, characterization, effector function (Fc) engineering, and clinical evaluation

by Md Harunur Rashid
Published 2022-12-01

Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors

by Susanne Wingert, Uwe Reusch, Stefan Knackmuss, Michael Kluge, Michael Damrat, Jens Pahl, Ute Schniegler-Mattox, Thomas Mueller, Ivica Fucek, Kristina Ellwanger, Michael Tesar, Torsten Haneke, Joachim Koch, Martin Treder, Wolfgang Fischer, Erich Rajkovic
Published 2021-01-01

TNB-486 induces potent tumor cell cytotoxicity coupled with low cytokine release in preclinical models of B-NHL

by Harbani K. Malik-Chaudhry, Kirthana Prabhakar, Harshad S. Ugamraj, Andrew A. Boudreau, Benjamin Buelow, Kevin Dang, Laura M. Davison, Katherine E. Harris, Brett Jorgensen, Heather Ogana, Duy Pham, Ute Schellenberger, Wim Van Schooten, Roland Buelow, Suhasini Iyer, Nathan D. Trinklein, Udaya S. Rangaswamy
Published 2021-01-01

Polyreactivity and polyspecificity in therapeutic antibody development: risk factors for failure in preclinical and clinical development campaigns

by Orla Cunningham, Martin Scott, Zhaohui Sunny Zhou, William J.J. Finlay
Published 2021-01-01

Antibodies to watch in 2021

by Hélène Kaplon, Janice M. Reichert
Published 2021-01-01

Collecting antibodies and large molecule biomarkers in mouse interstitial brain fluid: a comparison of microdialysis and cerebral open flow microperfusion

by Florie Le Prieult, Erica Barini, Loic Laplanche, Kerstin Schlegel, Mario Mezler
Published 2021-01-01

Enhancing the multi-attribute method through an automated and high-throughput sample preparation

by Pongkwan Sitasuwan, Thomas W. Powers, Tiffany Medwid, Yuting Huang, Bradley Bare, L. Andrew Lee
Published 2021-01-01

Characterization of a single reporter-gene potency assay for T-cell-dependent bispecific molecules

by Ho Young Lee, Ames Register, Jeongsup Shim, Edward Contreras, Qiang Wu, Guoying Jiang
Published 2019-10-01

In memoriam: Jefferson Foote

by E. Sally Ward, Peter Jones, Tim Buss, Cristina Rada, Gregory Winter, Richard Willson
Published 2021-01-01

Protective antibodies against human parainfluenza virus type 3 infection

by Jim Boonyaratanakornkit, Suruchi Singh, Connor Weidle, Justas Rodarte, Ramasamy Bakthavatsalam, Jonathan Perkins, Guillaume B.E. Stewart-Jones, Peter D. Kwong, Andrew T. McGuire, Marie Pancera, Justin J. Taylor
Published 2021-01-01

Coming together at the hinges: Therapeutic prospects of IgG3

by Thach H. Chu, Edward F. Patz, Margaret E. Ackerman
Published 2021-01-01

A matrix of structure-based designs yields improved VRC01-class antibodies for HIV-1 therapy and prevention

by Young D. Kwon, Mangaiarkarasi Asokan, Jason Gorman, Baoshan Zhang, Qingbo Liu, Mark K. Louder, Bob C. Lin, Krisha McKee, Amarendra Pegu, Raffaello Verardi, Eun Sung Yang, VRC Production Program, Kevin Carlton, Nicole A. Doria-Rose, Paolo Lusso, John R. Mascola, Peter D. Kwong
Published 2021-01-01

Selective depletion of radiolabeled HER2-specific antibody for contrast improvement during PET

by Priyanka Khare, Wei Sun, Sreevidhya Ramakrishnan, Rafal Swiercz, Guiyang Hao, Su-Tang Lo, Kien Nham, Xiankai Sun, Raimund J. Ober, E. Sally Ward
Published 2021-01-01

Half-life extension and non-human primate pharmacokinetic safety studies of i-body AD-114 targeting human CXCR4

by Katherine Griffiths, Uli Binder, William McDowell, Rita Tommasi, Mark Frigerio, William G. Darby, Chris G. Hosking, Lionel Renaud, Matthias Machacek, Peter Lloyd, Arne Skerra, Michael Foley
Published 2019-10-01

An end-to-end automated platform process for high-throughput engineering of next-generation multi-specific antibody therapeutics

by Norbert Furtmann, Marion Schneider, Nadja Spindler, Bjoern Steinmann, Ziyu Li, Ingo Focken, Joachim Meyer, Dilyana Dimova, Katja Kroll, Wulf Dirk Leuschner, Audrey Debeaumont, Magali Mathieu, Christian Lange, Werner Dittrich, Jochen Kruip, Thorsten Schmidt, Joerg Birkenfeld
Published 2021-01-01

Preclinical characterization of dostarlimab, a therapeutic anti-PD-1 antibody with potent activity to enhance immune function in in vitro cellular assays and in vivo animal models

by Sujatha Kumar, Srimoyee Ghosh, Geeta Sharma, Zebin Wang, Marilyn R. Kehry, Margaret H. Marino, Tamlyn Y. Neben, Sharon Lu, Shouqi Luo, Simon Roberts, Sridhar Ramaswamy, Hadi Danaee, David Jenkins
Published 2021-01-01

The influence of antibody engineering on Fc conformation and Fc receptor binding properties: Analysis of FcRn-binding engineered antibodies and an Fc fusion protein

by Takuo Suzuki, Noritaka Hashii, Minoru Tada, Akiko Ishii-Watabe
Published 2021-01-01

Calculation of therapeutic antibody viscosity with coarse-grained models, hydrodynamic calculations and machine learning-based parameters

by Pin-Kuang Lai, James W. Swan, Bernhardt L. Trout
Published 2021-01-01